Dyadic Association Between New Parents' Mindfulness and Relationship Satisfaction: Mediating Role of Perceived Stress.

The transition to parenthood is marked by increased potential stressors and relationship satisfaction declines among new parents. Recently, it has been suggested that people with greater mindfulness perceived their environment as less stressful during difficult times in life, which in turn, is associated with greater relationship satisfaction. Accordingly, this dyadic diary study evaluated if perceived stress explains the link between new parents' mindfulness and relationship satisfaction.

Conditional regard, stress, and dyadic adjustment in primiparous couples: A dyadic analysis perspective.

Many couples transitioning into parenthood are at risk for dyadic adjustment declines. It is therefore important to explore key, theory-driven deterrents of enduring relationships during this period, as well as potential underlying mechanisms. This study examined the relationship between perceived conditional negative regard (i.

Child Care Services, Socioeconomic Inequalities, and Academic Performance.

Objective: To determine if child-care services (CCS) at a population level can reduce social inequalities in academic performance until early adolescence.

Methods: A 12-year population-based prospective cohort study of families with a newborn (n = 1269). Two CCS variables were estimated: "intensity" (low, moderate, and high number of hours) and "center-based CCS type" (early onset, late onset, and never exposed to center-based CCS).

Alzhemed: a potential treatment for Alzheimer's disease.

As a potential disease-modifying treatment for AD, Alzhemed (tramiprosate) is a compound that binds to soluble amyloid-beta peptide (Abeta) and inhibits the formation of neurotoxic aggregates that lead to amyloid plaque deposition in the brain. The safety, tolerability, and pharmacodynamic effects of Alzhemed were assessed in a double-blind study in which 58 individuals with mild-to-moderate AD (MMSE 13-25) were randomized to receive placebo or Alzhemed 50, 100 or 150 mg BID for 3 months. At the end of the double-blind phase, 42 of these subjects entered a 36-month open-label (OL) phase in which they received Alzhemed 150 mg BID.

A phase 2 study of tramiprosate for cerebral amyloid angiopathy.

Background And Purpose: No treatments have been identified to lower the risk of intracerebral hemorrhage due to cerebral amyloid angiopathy (CAA). A potential approach to prevention is the use of agents that interfere with the pathogenic cascade initiated by the beta-amyloid peptide (Abeta). Tramiprosate (3-amino-1-propanesulfonic acid) is a candidate molecule shown in preclinical studies to reduce CAA in a transgenic mouse model.

Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis.

Amyloid beta-peptide (Abeta) is a major constituent of senile plaques in Alzheimer's disease (AD). Neurotoxicity results from the conformational transition of Abeta from random-coil to beta-sheet and its oligomerization. Among a series of ionic compounds able to interact with soluble Abeta, Tramiprosate (3-amino-1-propanesulfonic acid; 3APS; Alzhemedtrade mark) was found to maintain Abeta in a non-fibrillar form, to decrease Abeta(42)-induced cell death in neuronal cell cultures, and to inhibit amyloid deposition.